Ropeginterferon alfa-2b

Besremi

百斯瑞明針筒裝注射液劑

500mcg/1ml/syringe

03. ANTIMICROBIALS; ;

03.10. ANTIVIRALS;;

Biological Response Modulator; Interferon

治療不具症狀性脾腫大之成人真性紅血球增多症

X 動物或人體的試驗中或使用經驗發現對胎兒有害，而造成的傷害明顯大於可能的益處。

Unknown

Initial 100mcg SC once every 2 weeks, or 50 mcg once every 2 weeks (in combination with hydroxyurea); increase the dose by 50 mcg every 2 weeks (maximum: 500 mcg), until hematological parameters are stabilized Duration of therapy
Maintain the 2-week dosing interval (at the dose at which hematological stability is achieved) for at least 1.5 year. After 1.5 year of hematologic stability on a stable dose, the dosing interval may be increased to once every 4 weeks.

Leukopenia, thrombocytopenia, arthralgia, fatigue, Flu-like symptoms

甲狀腺疾病、有嚴重精神疾病或病史、嚴重心血管疾病、自體免疫疾病或病史、有接受器官移植者、與telbivudine合併治療、代償性肝硬化(Child-Pugh B或C)、末期腎臟疾病

1.冷藏於2-8℃
2.僅供皮下注射
3.曾有眩暈、嗜睡或幻覺之不良反應報告，應避免駕駛或操作機器

建立者

103617

建立時間

2023-02-03 08:42:43

維護者

103617

維護時間

2023-02-03 08:47:08